RenovoRx reports Q3 net loss $2.5M vs $1.4M last year

Cash and cash equivalents as of September 30, 2024, were $9.6 million. “We made significant progress in the third quarter of 2024 towards our goal of patient enrollment completion of our pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer, which is expected in the first half of 2025,” said Shaun Bagai, CEO of RenovoRx (RNXT). “In parallel, we have made important headway on commercialization plans for our FDA-cleared RenovoCath delivery system, creating the potential for near-term revenue generation.”